Understanding the Market | CanSinoBIO rises over 4% again, with third-quarter net profit increasing more than 8 times year-on-year, and core product ManHaiXin experiencing significant growth
CANSINOBIO rose over 4% again, as of the time of writing, it increased by 3.84%, trading at HKD 45.98, with a transaction volume of HKD 25.5136 million. In terms of news, CANSINOBIO released its performance report, achieving an operating income of 310 million yuan in the third quarter, a year-on-year increase of 17.67%; the net profit attributable to shareholders of the listed company was 27.9256 million yuan, a year-on-year increase of 842.01%. In the first three quarters, it achieved an operating income of 693 million yuan, a year-on-year increase of 22.13%; the net profit attributable to shareholders of the listed company was 14.4401 million yuan, turning from loss to profit year-on-year. The announcement stated that the strong growth in CANSINOBIO's third-quarter performance was mainly due to the market performance of its core product, ManHaiXin. As one of the only four-valent meningococcal conjugate vaccine products in the field of meningococcal vaccines in China, ManHaiXin has demonstrated strong market performance due to its innovative advantages, continuously increasing its market share and driving the company's revenue growth of 22.13% year-on-year in the first three quarters
According to the Zhitong Finance APP, CanSinoBIO (06185) has risen over 4% again, as of the time of writing, it is up 3.84%, priced at HKD 45.98, with a transaction volume of HKD 25.5136 million.
In terms of news, CanSinoBIO released its performance report, achieving an operating income of CNY 310 million in the third quarter, a year-on-year increase of 17.67%; the net profit attributable to shareholders of the listed company was CNY 27.9256 million, a year-on-year increase of 842.01%. In the first three quarters, the operating income reached CNY 693 million, a year-on-year increase of 22.13%; the net profit attributable to shareholders of the listed company was CNY 14.4401 million, turning from loss to profit year-on-year.
The announcement stated that the strong growth in CanSino's third-quarter performance was mainly due to the market performance of its core product, the MenQuadfi vaccine. As one of the only four-valent meningococcal conjugate vaccine products in the field of meningitis vaccines in China, MenQuadfi has demonstrated strong market performance due to its innovative advantages, achieving a continuous increase in market share, which drove the company's revenue growth of 22.13% year-on-year in the first three quarters
